fbpx
Register Log-in Investor Type

Healthcare News

This sector includes biotechnology, pharmaceuticals, research services, home healthcare, hospitals, long-term care facilities, and medical equipment and supplies. Companies in this sector include Astra Zeneca, Pfizer and Roche Holding.

23 Nov 2022

QuotedData’s morning briefing 23 November 2022

In QuotedData’s morning briefing 23 November 2022: Worldwide Healthcare (WWH) has announced its interim results for the six months ended 30 September 2022. During the period, WWH provided an NAV total return of 3.1%, modestly outperforming its benchmark, the MSCI World Healthcare Index, which returned 2.1% during the period. In absolute terms, net asset value […]

21 Nov 2022
WPCT-backed Immunocore enters Phase I with lead GSK project

BioPharma Credit provides senior loan to Immunocore

BioPharma Credit (BPCR) has announced that, together with BioPharma Credit Investments V, it has entered into a senior secured loan agreement with Immunocore Limited. BPCR will invest up to US$50m and BioPharma-V will also invest up to an additional US$50m. Based in the UK, Immunocore is a publicly traded biopharmaceutical company with a current market […]

18 Nov 2022

Conviction Life Sciences publishes prospectus for £100m IPO

A new Guernsey domiciled investment company, Conviction Life Sciences (CLSC), published a prospectus on 16 November 2022 for its initial public offering (IPO). The prospectus is availale here. The IPO is targeting gross proceeds of £100m and CLSC plans to list on the main market of the London Stock Exchange. It is expected that CLSC’s […]

28 Oct 2022

QD view – Biotech sector is ripe for investment but collectives are the way forward

Biotechnology is an exciting and potentially rewarding sector for investment but for the private investor it is also risky and probably best addressed through collective investment vehicles. After all, development of new drugs is hugely expensive (and thus funding-dependent), scientifically uncertain and fraught with operational challenges and pitfalls. And adding to this is the fact […]

04 Oct 2022

BB Biotech’s enters Q4 with NAV rise on Myovant buyout offer

BB Biotech saw an almost 3% rise in its NAV yesterday to CHF51/share, helped by a 36% jump in the share price in one of its holdings – Myovant – triggered by a cash buy-out offer. BB Biotech’s share price, however, was largely unchanged at CHF52.8, which has had the effect of reducing the investment […]

23 Sep 2022

BB Biotech’s latest investment hints at broader strategy

Switzerland’s BB Biotech has opened a new investment position in Rivus Pharmaceuticals, a privately held US biotech developing a mitochondrial-based approach to obesity and cardio-metabolic disease. This was made as part of a $132m Series B financing that is notable for its size and the top-tier syndicate of healthcare specialist investors who have participated. The […]

16 Sep 2022

QuotedData’s morning briefing 16 September 2022

In QuotedData’s morning briefing 16 September 2022: RTW Venture’s (RTW’s) portfolio company, Third Harmonic Bio Inc., has completed its initial public offering (IPO) and has listed on Nasdaq (ticker: THRD). The upsized issue raised US$185.3m by offering around 10.7m shares at US$17.00 per share. Third Harmonic Bio is a clinical-stage biotechnology company developing a first-in-class, […]

22 Jul 2022

QD view – Is the tide finally turning for biotech?

In early 2021, it looked like the pandemic had been a breakthrough moment for the biotechnology sector. The sector had been critical in the development of Covid-19 vaccines, using new and innovation gene sequencing, while developments in oncology promised a treatment revolution. Share prices were riding high and specialist investment trusts had enjoyed two years […]

15 Jul 2022

BB Biotech shares rise as sector sees signs of recovery

BB Biotech shares closed yesterday at CHF 57 per share, down 26.5% in the year-to-date period, but crucially up by 12% since mid-June when the shares hit a recent nadir of CHF51 per share. NAV, at CHF49.95 per share, is down by 9.95% year-to-date (YTD), but has gained 22% from its recent nadir of CHF40.9 […]

16 Jun 2022

Syncona well-placed to back its portfolio through adverse market

Syncona’s results for the financial year ended 31 March 2022 show an NAV total return of just 0.3%. However, this was a long way ahead of the -12% return on the NASDAQ Biotechnology Index. A significant NAV uplift achieved through the sale of Gyroscope to Novartis and multiple successful private financings offset the decline in […]

27 May 2022

Major underperformance for Worldwide Healthcare

Following the announcement earlier today that it has terminated its placing programme (click here to read more), Worldwide Healthcare (WWH) has now announced its annual results for the year ended 31 March 2022. These show that, following the previous year’s strong returns, both on an absolute and on a relative basis, the year under review […]

27 May 2022

QuotedData’s morning briefing 27 May 2022

In QuotedData’s morning briefing 27 May 2022: Worldwide Healthcare (WWH) has announced that it is terminating its placing programme, which was established on 13 July 2021, with immediate effect. WWH expects to publish its annual results later today and, if the placing programme was still in effect, this would have required WWH to publish a […]

13 May 2022

QuotedData’s morning briefing 13 May 2022

In QuotedData’s morning briefing 13 May 2021: Barings Emerging EMEA Opportunities (BEMO) has announced that Maria Szczesna, one of its investment managers, and a member of the Barings EMEA Team, has decided to step down from her portfolio management responsibilities to return to her home country for family reasons. Maria will remain with BEMO until […]

09 May 2022

BB Biotech remains resilient as biotech markets worsen

BB Biotech (SWX:BION) has continued to show a resilient performance this year, a period that has proved to be extremely challenging for biotech investing – indeed the sector is now considered to be experiencing its most severe bear market for more than two decades. BB Biotech’s shares closed on Friday at CHF 56.00, down 23% […]

04 Apr 2022

BB Biotech remains resilient in another difficult quarter

BB Biotech (SWX:BION) showed a resilient investment performance in an extremely difficult period for biotech in the first quarter this year, although its NAV, share price and long standing premium have all clearly come under pressure. The Swiss investment company closed the first quarter of 2022 with its shares trading at CHF65.4, down by 10.3%, […]

11 Mar 2022

QuotedData’s morning briefing 11 March 2022

In QuotedData’s morning briefing 11 March 2022: CQS Natural Resources Growth and Income (CYN) has announced its interim results for the six months ended 31 December 2021. CYN’s chairman, Richard Prickett says that, during the period, commodity markets were strong and interestingly for the sector higher interest rate expectations are supporting a broad market rotation […]

17 Feb 2022

RTW makes two investments

RTW makes two investments: Magnolia Medical Technologies RTW says that Magnolia Medical Technologies has completed a $46m growth equity financing round. The company, alongside other investment vehicles of RTW Investments, LP, participated in the financing round together with other investors. Magnolia Medical is a privately held medical technology company that develops, manufactures, and markets innovative […]

21 Jan 2022

BB Biotech sees compelling opportunities at current biotech valuations

With valuations in biotech having fallen substantially in the last year, BB Biotech (SWX: BION) sees compelling opportunities in the small-to-mid cap space this year and believes some of its core portfolio companies, such as Neurocrine, Incyte and Ionis Pharmaceuticals, could see interest from strategic investors, including as M&A targets. The comments come in the […]

17 Jan 2022

BB Biotech resilient in challenging period for portfolio

BB Biotech (SWX: BION) seems to be resilient in the current challenging period for biotech investing and most especially in the last week, which ranks as one of the most important trading periods in the biotech calendar. The Swiss investment company saw a 0.8% fall in its NAV in the five days from January 10-14th […]

04 Jan 2022

Investors reward BB Biotech despite turbulent year

Swiss investment company BB Biotech (SWX:BION) closed 2021 with its shares trading at CHF77.15, a rise by 8.3% over the year. However, the positive stock performance contrasts with an 11.4% fall in its NAV to CHF59.4/share in 2021, which was adversely affected by the severe bear market for biotech – and particularly its small to […]

17 Dec 2021

Strong outperformance from Polar Capital Global Healthcare

Polar Capital Global Healthcare (PCGH) has released its annual results for the year ended 30 September 2021, during which it has provided NAV and share price total returns of 19.46% and 24.55%, strongly outperforming its benchmark, the MSCI ACWI Health Care Index, which returned 13.40%. Since its restructuring to 30 September 2021, PCGH has provided […]

16 Dec 2021

Syncona’s Anaveon secures Series B financing

Syncona’s Anaveon secures Series B financing – Syncona has committed CHF35m (£29m) to Anaveon AG as part of a CHF110m (£90m) Series B financing round. Syncona was a cornerstone investor. The financing round was led by Forbion and supported by a leading international syndicate of specialist investors, including existing investor Novartis Venture Fund and new investors […]

04 Nov 2021

Syncona backs launch of Clade Therapeutics

Syncona backs launch of Clade Therapeutics – Syncona was the lead investor in the $87m Series A financing of Clade Therapeutics, a new cell therapy company. Syncona’s commitment was $30m and the first tranche of that  – $15.0m – has been invested already. Syncona’s stake in the company is 22.6% (assuming all commitments are invested). […]

23 Sep 2021

BB Biotech discloses a third bargain top up this quarter

BB Biotech has disclosed an increase in its holding in Mersana Therapeutics (Nasdaq:NRSN), the timing of which suggests it again aims to capitalise on a 40% fall in an investee company’s share price that occurred after a clinical trial update earlier in the month. The Swiss investment company disclosed the increased holding in a SEC […]

10 Sep 2021

QuotedData’s morning briefing 10 September 2021

In QuotedData’s morning briefing 10 September 2021: RTW Venture (RTW) has announced a new portfolio investment in Lycia Therapeutics, following its participation in the company’s US$70m series B financing round, the proceeds of which are intended to advance Lycia’s discovery pipeline of LYTAC degraders. Lycia is a privately held biotechnology company developing extracellular protein degradation […]

10 Aug 2021

Stellar Moderna share drives BB Biotech back to near all time high

Swiss investor BB Biotech’s (SWX:BION) large position in US covid vaccine producer Moderna continues to drive a remarkable performance in a volatile US biotech market. Yesterday, Moderna (Nasdaq: MRNA) surged 17% to a new all-time high of $484.5/share, giving it a market capitalisation of $167bn. Moderna is the largest of BB Biotech’s holdings accounting for […]

23 Jul 2021

Moderna drives strong performance at BB Biotech

BB Biotech’s (SWX:BION) large position in US covid vaccine producer Moderna drove a strong performance against a volatile US biotech market in the first half of this year. Moderna was the second best performer within BB Biotech’s portfolio during the period, with a rise of 105%, beaten only by Essa Pharmaceuticals, whose stock was up […]

05 Jul 2021

QD view – Volatility remains hallmark of biotech in first half

Essa Pharmaceutials (Nasdaq: EPIX) and Moderna (MRNA) may have been the top performers within Swiss investment company BB Biotech’s (SIX:BION) 34-strong portfolio in the first half, sporting stock price rises of 137% and 124% respectively, but these gains are modest by comparison with some of the ones from within the wider world of biotech investing. […]

01 Jul 2021

BB Biotech ends volatile Q2 on a (near) all-time high

BB Biotech (SWX:BION) ended the first half with its shares up 22.2% and at CHF87 at the close yesterday, just 5% below their all-time high of CHF90 that was reached in February. The Swiss investment company’s net asset value grew by 8.9% in the first half to CHF73.1 per share, which seems to be a […]

15 Jun 2021

RTW backs Umoja Biopharma

RTW backs Umoja Biopharma – Umoja Biopharma, Inc. has just completed a $210m Series B financing round. RTW Venture Fund participated in the financing round together with other investment firms, including other investment vehicles of RTW Investments, LP. Umoja is a US-based privately held oncology company. It is using a new approach to immunotherapy, reprogramming immune cells directly […]

Please review our cookie, privacy & data protection and terms and conditions policies and, if you accept, please select your place of residence and whether you are a private or professional investor.

You live in…

You are a…